Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is available in both forms. The original, long-established version is a once-weekly injection; a once-daily tablet was approved by the MHRA on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. Both forms contain semaglutide, both require a prescription following a clinical assessment, and the right choice depends on your health profile and how you prefer to take a medicine. A prescriber decides which is suitable for you — not a quiz, not a calculator.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The injection form has been available in the UK since 2023. It comes as a pre-filled pen that you use once a week, injecting under the skin of your abdomen, thigh, or upper arm. The pen contains semaglutide at doses running from 0.25mg up to a standard maintenance dose of 2.4mg, with the MHRA having also approved a higher 7.2mg pen in April 2026 for adults with a BMI of 30 or above. Titration happens gradually, roughly every four weeks, to give your body time to adjust.
The tablet is newer. Approved on 11 June 2026, it follows a different escalation: 1.5mg, then 4mg, then 9mg, reaching a 25mg maintenance dose. Those strengths are specific to Wegovy tablets, worth knowing, because another semaglutide tablet called Rybelsus uses different doses (3mg, 7mg, 14mg) and is licensed for type 2 diabetes, not weight loss. They are not interchangeable.
The active ingredient in both is identical. What changes is the delivery method, the dosing schedule, and a few practical details that genuinely matter day to day. If you're wondering whether Wegovy comes as a pill or an injection, both forms are now licensed in the UK, and our dedicated page walks through each one. You can read more about the tablet specifically on our semaglutide tablets page, and if you want a side-by-side view of Wegovy oral or injection, we cover the key differences there too.
Storage is where the two forms diverge most visibly. The injection pen needs to live in the fridge (typically in the door, where the temperature stays consistent) until you're ready to use it. Take it out about 30 minutes before injecting to let it reach room temperature. The tablet needs none of that; it sits in a drawer or a bag at room temperature, which some people find far simpler, especially when travelling or staying away from home.
How you take each one also differs. The tablet goes first thing in the morning, before anything else, swallowed whole with a small amount of plain water, then a wait of at least 30 minutes before food, coffee, or other medicines. That timing window is non-negotiable for the medicine to absorb properly. The injection, by contrast, can be taken at any time of day (though consistency week to week helps), with or without food.
On effectiveness: the injection at 2.4mg produced roughly 15% average body-weight reduction over 68 weeks in the STEP 1 trial, as published in the New England Journal of Medicine. The tablet, assessed in the OASIS 4 phase 3 trial over 64 weeks, showed around 13.6% average weight loss overall, and around 16.6% among participants who stayed fully adherent. The higher-dose 7.2mg injection narrows the gap further. These are population averages from clinical trials; individual results vary, and no specific outcome can be promised.
For people curious about how these two forms compare across the detail, our page on semaglutide pills vs injection covers the comparison more fully than we can here, including how side-effect profiles and absorption differ between the two.
Both forms are licensed for adults. The injection is licensed for a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. The 7.2mg pen applies only from BMI 30 upward.
The tablet shares broadly the same threshold: BMI 30 or above, or 27 to 29.9 with a qualifying condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, your prescriber can clarify whether that applies in your case.
Neither form is recommended during pregnancy, breastfeeding, or when trying to conceive. Neither is licensed for under-18s. A history of certain conditions (including medullary thyroid carcinoma or pancreatitis) requires careful prescriber assessment, as set out in the NHS guidance on weight management injections. BMI alone does not determine whether treatment is appropriate; the whole clinical picture does.
Neither Wegovy form is currently available on the NHS through a routine GP referral for most people. Waiting lists via specialist weight management services can be long. Private prescription through a regulated online pharmacy is the route many people use. If you want to understand the cost side of that, the semaglutide tablets price page explains what a private prescription typically includes and what to look out for.
This is the part that can't be shortcut. Both forms are prescription-only medicines under UK law, which means a qualified prescriber must assess your suitability before anything is dispensed. That assessment covers your medical history, any medicines you currently take, your BMI and weight-related conditions, and your preferences.
One practical point about the tablet: because it's taken orally and must be swallowed well before food, it interacts differently with other morning medications. A common question at this stage is whether semaglutide is taken orally or by injection, and the answer now depends on which product and licence applies to your situation, something your prescriber will work through with you. With the injection, a separate interaction consideration applies for women using oral contraceptives: NHS guidance on semaglutide explains the precautions to discuss with your prescriber.
At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not automated software) on the same day it's submitted. The prescriber considers both the injection and tablet options in light of your answers. If you're approved, treatment is dispatched the same day for next working day delivery, in plain packaging. You can also read about our clinical team on the clinical team profile page if you'd like to know more about who reviews your case.
If you're ready to find out which form suits your situation, check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.